{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-349170","form_type":"8-K","ticker":"ELDN","cik":"0001404281","company_name":"Eledon Pharmaceuticals, Inc.","filed_at":"2026-08-13T20:08:48+00:00","discovered_at":"2026-08-13T20:11:00.295197+00:00","generated_at":"2026-08-13T20:11:22.914804+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Eledon Q2 net loss $31.6M; cash $88.8M; Phase 3 kidney trial on track","bullets":["Cash $88.8M at June 30, 2026 vs $133.3M at Dec 31, 2025; expected to fund ops into Q2 2027.","Q2 net loss $31.6M ($0.27/share) vs $11.2M ($0.13) prior year; ex-warrant changes, loss $22.0M vs $23.5M.","FDA End-of-Phase 2 meeting supports Phase 3 kidney transplant trial of tegoprubart; ~600 patients, late 2026 start.","BESTOW 18-month data: eGFR ~12 mL/min higher vs tacrolimus (74 vs 61); no BPAR after 6 months in tegoprubart arm.","Islet cell study: all 12 T1D patients insulin-independent, mean HbA1c ~5.4%; Natera Prospera partnership for Phase 3."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-349170","json":"https://secwatch.observer/filing/0001193125-26-349170.json","markdown":"https://secwatch.observer/filing/0001193125-26-349170.md","text":"https://secwatch.observer/filing/0001193125-26-349170.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404281/000119312526349170/0001193125-26-349170-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404281/000119312526349170/eldn-20260813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T20:11:22.914804+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}